60 F
New York
Friday, May 7, 2021

Why Aptevo Therapeutics [NASDAQ: APVO] Skyrocketing Today?

Must read

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Aptevo Therapeutics Inc. [NASDAQ: APVO] kicked off the Monday session with a strong performance as its shares soared 89.87%. The strong performance of the company showed the positive sentiments of investors after it has shared an update on its ongoing APVO436 clinical trial.

A biotechnology company has reported that it has observed second complete remission in a Patient in cohort 6. Earlier, on November 6 the company has received the data regarding cohort 6. It has witnessed complete remission in the second patient.

Additionally, there are two patients who have showed the postive signs in cohort 6 of the clinical trial.

Shares of Aptevo Therapeutics Inc. [NASDAQ: APVO] went up 89.87% at $45.00 at the time of writing on Monday. It had recorded a trading volume of 3.01 million as compared to the average volume of 1.43 million.

Looking at its profitability, it has a return on assets (ROA) of -48.20% and returns on equity (ROE) of -137.20%. Focusing on its liquidity, it has a current ratio of 1.50. Furthermore, APVO has total market capitalization of $68.49 million at the time of writing.

A total of nine patients are enrolled in cohort 6 of the clinical trial. One patient has shown the stable disease status and 6 patients have experienced the progress in disease.

Furthermore, President and CEO of Aptevo Therapeutics, Marvin White, said that this is the greatest achievement of the company as two patients have shown the complete disappearacne of the disease. CEO revealed that the company has now started the enrollment for chort 8.

APVO436 is the bispecific antibody therapy that is manufactured on the next-generation proprietary ADAPTIR™ protein therapeutic platform of the Aptevo.

Additionally, this is an investigational therapy that is currently being assessed for the treatment of acute myeloid leukemia (AML).

Biotechnology company has also disclosed that it is scheduled to share two new new posters at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting. The meeting to be held on November 9, 2020 to Saturday, November 14, 2020.

More articles

Latest article

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...

R1 RCM [NASDAQ: RCM] Announces Acquisition of VisitPay

R1 RCM Inc. disclosed Tuesday that it has decided to purchase VisitPay. The firm has inked an agreement to buy VisitPay for nearly...

Binance Coin Makes History as its Market Cap Reach $100 Billion

The market capitalization of Binance set new records as the exchange token of Binance and the native asset of Binance Smart Chain (BSC) touched...

Precipio [NASDAQ: PRPO] Roll Out Rapid COVID-19 Antibody test on Amazon Platform

Shares of Precipio, Inc. skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments...

TechX Ink Deal to Buy Fiat-to-Crypto Merchant Services Gateway XPort Digital

TechX Technologies Inc disclosed Monday that it has bought fiat-to-crypto merchant services gateway XPort digital. The firm has bought a 100% stake in XPort...

Lockheed [NYSE: LMT] Present F-35 Best and Final Offer to Finnish Government

Lockheed Martin Corporation disclosed that it has presented F-35 best and final offer (BAFO) on April 29, 2021, to the Finnish government. It...

Clene [NASDAQ: CLNN] Gets Two Patent Notice of Allowances

Clene Inc. disclosed that Clene Nanomedicine, Inc. U.S. Patent and Trademark Office has provided Notices of Allowance for two significant patent applications. Clene...